NLS Agreement

Xbrane Biopharma and STADA have entered into an exclusive licensing agreement with US biosimilars specialist Valorum Biologics for their ranibizumab biosimilar candidate. Valorum will pay a license fee of up to USD 45 million, plus royalties on net product sales. This fee, plus royalties paid by Valorum on net sales of the product, will be […]

The two companies have entered into an agreement regarding BAN2802, a potential new treatment combining BioArctic’s BrainTransporter technology with an undisclosed Alzheimer drug candidate. At the end of the collaboration, Eisai will evaluate the data generated and decide if they chose to exercise an option to license BAN2802 for the treatment of Alzheimer’s disease. “I […]

BioInvent International has announced a clinical trial collaboration and supply agreement with MSD International Business for a Phase 1/2a study of its monoclonal antibody BI-1910 in combination with KEYTRUDA. Under the terms of the supply agreement, MSD will provide its anti-PD-1 therapy KEYTRUDA to be used in combination with BI-1910. The Phase 1/2a trial will […]

The two companies have announced a collaboration to commercialize Oncopeptides’ drug Pepaxti in the Middle East and North Africa countries of Saudi Arabia, Qatar, UAE, Bahrain, Kuwait, Oman, Algeria, Tunisia, Morocco, Libya, Lebanon, and Iraq. Under the terms of this exclusive agreement, Vector will distribute Pepaxti to patients in the MENA region for the treatment […]

The two companies will develop digital patient monitoring for people with advanced renal cell carcinoma (RCC), using Elekta’s Kaiku Health solution, a digital platform for patient engagement and reported outcomes monitoring. Elekta, with support from MSD, will develop a digital module for patients, keeping them connected with their care team, and educating them about their […]

Anocca and EmendoBio have announced a non-exclusive licensing agreement for the use of EmendoBio’s novel OMNI-A4 nuclease to accelerate the manufacture and development of Anocca’s deep pipeline of TCR-T cell therapies for difficult-to-treat solid cancers. “Integrating EmendoBio’s nuclease into our manufacturing process supports Anocca’s aim of generating the highest-quality cell therapy products. This next-generation gene […]